GPRC5D expression
GPRC5D is a receptor on myeloma cells and in hair follicles, nails and taste buds. Talquetamab targets it without any test, and the side effects on skin, nails and taste follow from where it is expressed.
Overview
Talquetamab (Talvey) is a GPRC5D x CD3 bispecific labelled for relapsed or refractory multiple myeloma after at least four prior lines; the label names GPRC5D only as the target. Expression on plasma cells is high and independent of BCMA, which is why GPRC5D-directed therapy works after BCMA failure; GPRC5D loss at relapse has been described.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · GPRC5D is a second myeloma target used when BCMA-directed drugs stop working.
Talquetamab is given without a GPRC5D test. Because the same receptor sits in your skin, nails and taste buds, changes in taste, dry mouth, rash and nail problems are expected and are managed rather than treated as a sign the drug is not working.
Written only from the label or guideline text cited on this page. Not medical advice; your own report and the reading your team gives it come first.
The label names the antigen in the drug's description but does not require it to be measured before treatment; no approval threshold exists for this readout.
“TALVEY is a bispecific GPRC5D-directed CD3 T-cell engager”
TALVEY prescribing information (DailyMed)No approval uses this readout as a threshold.
Matched on the name and aliases of the readout in the title, setting and summary of each trial; a match is a mention, not proof the readout was an entry criterion.
- NCT04634552 · 2022MonumenTAL-1
- NCT06615479A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- NCT06500884A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- NCT07455851A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
- NCT07523555Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
- NCT06297226Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Similar pages
not linked directly; found by shared links- BiomarkerB7-H3 (CD276) expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerCEACAM5 expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerDLL3 expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerHER3 expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerNectin-4 expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerTissue factor expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerTROP2 expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerCD22 expression (CD22-positive)
Shares Antigen escape (antigen loss, lineage switch) and the tags biomarker, surface-antigen.